Saccharomyces boulardii: Basic science and clinical applications in gastroenterology

Gastroenterology Clinics of North America

Volumn 34, Issue 3, 2005, Pages 515-532

  Buts, Jean Paul ^a   Bernasconi, Paul ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Service de Pharmacologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; MESALAZINE; METRONIDAZOLE; PROBIOTIC AGENT; STOMACH SECRETION INHIBITOR; VANCOMYCIN;

ACUTE GASTROENTERITIS; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; CROHN DISEASE; DIARRHEA; ENTERIC FEEDING; ENTERITIS; ENTEROPATHY; ESCHERICHIA COLI; FUNGEMIA; HUMAN; IMMUNOREACTIVITY; INFANTILE DIARRHEA; INTESTINE INFECTION; IRRITABLE COLON; NONHUMAN; PSEUDOMEMBRANOUS COLITIS; REVIEW; SACCHAROMYCES BOULARDII; TRAVELLER DIARRHEA;

ANIMALS; CLINICAL TRIALS; GASTROENTEROLOGY; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL DISEASES; MICE; SACCHAROMYCES;

EID: 23244467911     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2005.05.009     Document Type: Review

References (77)

1. L.V. McFarland, and P. Bernasconi Saccharomyces boulardii: a review of an innovative biotherapeutic agent Microb Ecol Health Dis 6 1993 151 171
2. G.W. Elmer, C.M. Surawicz, and L.V. McFarland Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal secretions JAMA 275 1996 870 876
3. C.M. Surawicz, G.W. Elmer, and P. Speelman Prevention of antibiotic associated diarrhea by Saccharomyces boulardii: a prospective study Gastroenterology 96 1989 981 988
4. L.V. McFarland, C.M. Surawicz, and R.N. Greenberg Prevention of β-lactam associated diarrhea by Saccharomyces boulardii compared with placebo Am J Gastroenterol 90 1995 439 448
5. L.V. McFarland, C.M. Surawicz, and R.N. Greenberg A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease JAMA 271 1994 1913 1918
6. C.M. Surawicz, L.V. McFarland, and R. Greenberg The search for better treatment for Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii Clin Infect Dis 31 2000 1012 1017
7. J.P. Buts, G. Corthier, and M. Delmée Saccharomyces boulardii for Clostridium difficile-associated enterocolopathies in infants J Pediatr Gastroenterol Nutr 16 1993 1497 1504
8. W. Höchter, D. Chase, and G. Hegenhoff Saccharomyces boulardii in treatment of acute adult diarrhea. Efficacy and tolerance of treatment MMW Münch Med Wochenschr 132 1990 188 192
9. G. Cetina-Sauri, and G. Sierra Basto Evaluation thérapeutique du Saccharomyces boulardii chez des enfants souffrant de diarrhée aiguë Ann Pediatr 41 1994 397 400
10. H. Kollaritsch, H. Holst, and P. Grobara Prophylaxe der Reisediarrhoë mith Saccharomyces boulardii Fortschr Med 111 1993 152 156
11. J.P. Buts Exemple d'un médicament probiotique: Saccharomyces boulardii lyophilisé J.C. Rambaud J.P. Buts G. Corthier Flore microbienne intestinale: physiologie et pathologie digestives 2004 John Libbey Eurotext Montrouge, (France) 221 244
12. G. Bleichner, H. Bléhaut, H. Mentec, and D. Moyse Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multi-center, randomised, double-blind, placebo-controlled trial Intensive Care Med 23 1997 517 523
13. T. Saint-Marc, H. Bléhaut, and C. Musial Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA Annales de Medicine Interne 142 1991 64 65
14. M. Guslandi, G. Mezzi, M. Sorghi, and P.A. Testoni Saccharomyces boulardii in maintenance treatment of Crohn's disease Dig Dis Sci 45 2000 1462 1464
15. M. Guslandi, P. Giollo, and P.A. Testoni A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15 2003 697 698
16. C. Hennequin, A. Thierry, and G.F. Richard Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains J Clin Microbiol 39 2001 551 559
17. J.Y. Malgoire, S. Bertout, and F. Renaud Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism J Clin Microbiol 43 2005 1133 1137
18. E. Bergogne-Berezin Impact écologique de l'antibiothérapie. Place des microorganismes de substitution dans le contrôle des diarrhées et colites associées aux antibiotiques Presse Méd 24 1995 145 156
19. J.P. Buts Mechanisms of action of biotherapeutic agents G.W. Elmer L.V. McFarland C.M. Surawicz Biotherapeutic agents and infectious diseases 1999 Humana Press Totowa (NJ) 27 46
20. H. Bléhaut, J. Massot, and G.W. Elmer Disposition kinetics of Saccharomyces boulardii in man and rat Biopharm Drug Dispos 10 1989 353 364
21. D. Czerucka, J. Roux, and P. Rampal Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′, 5′-cyclic monophosphate induction in intestinal cells Gastroenterology 106 1994 65 72
22. C. Pothoulakis, C.P. Kelly, and M.A. Joshi Saccharomyces boulardii inhibits Clostridium difficile toxin A and enterotoxicity in rat ileum Gastroenterology 103 1993 1108 1115
23. I. Castagliulo, M.F. Riegler, and L. Valenick Saccharomyces boulardii protease mediates Clostridium difficile toxin A and B effects in human colonic mucosa Infect Immun 61 1999 302 307
24. D. Czerucka, S. Dahan, and B. Mograbi Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli infected T84 cells Infect Immun 68 2000 5998 6004
25. D. Czerucka, S. Dahan, and B. Mograbi Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection Infect Immun 69 2001 1298 1305
26. J.P. Buts, P. Bernasconi, and J.P. Vaerman Stimulation of secretory IgA and secretory component of immunoglobulins in the small intestine of rats treated with Saccharomyces boulardii Dig Dis Sci 35 1990 251 256
27. J.P. Buts, P. Bernasconi, and M.P. Van Craynest Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii Pediatr Res 20 1986 192 196
28. J.P. Buts, N. De Keyser, and S. Marandi Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats Gut 45 1999 89 96
29. D. Czerucka, and P. Rampal Experimental effects of Saccharomyces boulardii on diarrheal pathogens Microbes Infect 4 2002 733 739
30. R.D. Toothaker, and G.W. Elmer Prevention of clindamycin-induced mortality in hamster by Saccharomyces boulardii Antimicrob Agents Chemother 26 1984 552 556
31. G. Corthier, F. Dubois, and R. Ducluzeau Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii Can J Microbiol 32 1986 294 296
32. G. Corthier, F. Lucas, and S. Jouvet Effect of oral Saccharomyces boulardii treatment on activity Clostridium difficile toxins in mouse digestive tract Toxicon 30 1992 1583 1589
33. J. Massot, O. Sanchez, and R. Couchy Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin induced colitis in the hamster Arzneimittelforschung 34 1984 794 797
34. F. Castex, G. Corthier, and S. Joubert Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study J Gen Microbiol 136 1990 1085 1089
35. D. Czerucka, J.L. Nano, and P. Bernasconi Réponse aux toxines A et B de Clostridium difficile d'une lignée de cellules épithé liales de rat: IRD 98. Effet de Saccharomyces boulardii Gastroenterol Clin Biol 15 1991 22 27
36. G.W. Elmer, and G. Corthier Modulation of Clostridium difficile induced mortality as a function of the dose and viability of the Saccharomyces boulardii used as preventive agent in gnotobiotic mice Can J Microbiol 37 1991 315 317
37. I. Castagliuolo, J.T. LaMont, and S.T. Nikulasson Saccharomyces boulardii protease mediates Clostridium difficile toxin A effects in rat ileum Infect Immun 12 1996 5225 5232
38. A. Qamar, S. Aboudala, and M. Warny Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice Infect Immun 69 2001 2762 2765
39. A. Tasteyre, M.C. Barc, and T. Karjalainen Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii Microb Pathog 32 2002 219 225
40. V. Vidon, B. Huchet, and J.C. Rambau Influence de Saccharomyces boulardii sur la sécrétion jéjunale induite chez le rat par la toxine cholérique Gastroenterol Clin Biol 10 1986 13 16
41. D. Czerucka, J.L. Nano, and P. Bernasconi Réponse à la toxine cholérique de deux lignées de cellules épithé liales intestinales. Effet de Saccharomyces boulardii Gastroenterol Clin Biol 13 1989 383 387
42. - secretion in T84 cells Dig Dis Sci 44 1999 2359 2368
43. K.A. Barrett Positive and negative regulation of chloride secretion Am J Physiol 265 1993 C859 C868
44. C.J. Venglarik, R.J. Bridges, and R.A. Frizel A simple assay for agonist-regulated Cl and K conductances in salt-secreting epithelial cells Am J Physiol 259 1990 C358 C360
45. J. Massot, M. Descanclois, and J. Astoin Protection par Saccharomyces boulardii de la diarrhée à Escherichia coli du souriceau Ann Pharm Fr 40 1982 445 449
46. P.J. Philpott, D.M. McKay, and P.M. Sherman Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions Am J Physiol 33 1998 G634 G645
47. S.D. Savkovic, A. Koutsouris, and G. Hecht Attachment of a non invasive enteric pathogen, enteropathogenic Escherichia coli, to cultured human intestinal epithelial monolayers induces transmigration of neutrophils Infect Immun 64 1996 4480 4487
48. R. Yuhan, A. Koutsovris, and S.D. Savkovic Enteropathogenic Escherichia coli induced myosin light chain phosphorylation alters intestinal epithelial permeability Gastroenterology 113 1997 1873 1882
49. S. Dahan, G. Dalmasso, and V. Imbert Saccharomyces boulardii interferes with enterohemorragic Escherichia coli induced signaling pathways in T84 cells Infect Immun 71 2003 766 773
50. S. Dahan, V. Bussatil, and V. Imbert Enterohemorragic Escherichia coli infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappa B and AP-1 in T84 cells Infect Immun 70 2002 2304 2310
51. S. Marandi, N. De Keyser, and C. Stilmant Ontogeny of MAP kinases in rat small intestine: premature stimulation by insulin of BBM hydrolases is regulated by ERKs but not by p-38 MAP kinase Pediatr Res 5 2 2002 180 188
52. S. Marandi, N. De Keyser, and A. Saliez Insulin signal transduction in rat small intestine: role of MAP kinases in expression of mucosal hydrolases Am J Physiol Gastrointest Liver Physiol 280 2 2001 G229 G240
53. S. Hobbies, L.M. Chen, and R.J. Davis Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells J Immunol 57 1997 1290 1298
54. P. Tang, Y.A. Sutherland, and M.R. Gold Listeria monocytogenes invasion of epithelial cells requires the MEK-1/MEK-2 mitogen-activated protein kinase pathway Infect Immun 66 1998 1106 1112
55. A.C.P. Rodrigues, R.M. Nardi, and E.A. Bambirra Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri conventional and gnotobiotic mice J Appl Bacteriol 91 1996 251 256
56. H.U. Jahn, R. Ullrich, and T. Schneider Immunology and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers Digestion 57 1996 95 104
57. H.K. Harms, R.M. Bertele-Harms, and D. Bruer-Kleis Enzyme substitution therapy with the yeast Saccharomyces boulardii in congenital sucrase-isomaltase deficiency N Engl J Med 316 1987 1306 1309
58. J.P. Buts, N. De Keyser, and C. Stilmant Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat intestine by endoluminal release of a zinc-binding metalloprotease Pediatr Res 51 2002 528 534
59. A. Zaouche, C. Loukil, and P. de la Gausie Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation and intestinal adaptation after small bowel resection in rats Scand J Gastroenterol 35 2000 160 165
60. J.P. Buts, N. De Keyser, and L. De Raedemaeker Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines Pediatr Res 36 1994 522 527
61. T.F. Bowling, A.H. Raimundo, and G.K. Grimble Reversal by short-chain fatty acids of colonic fluid secretion induced by enteral feeding Lancet 342 1993 1266 1268
62. G. Breves, K. Faul, and B. Schröder Application of the colon-stimulation technique for studying the effects of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin Digestion 61 2000 193 200
63. M. Krammer, and U. Karbach Antidiarrheal action of the yeast Saccharomyces boulardii in the rat small and large intestine by stimulating chloride absorption Z Gastrenterol 31 1993 73 77
64. P. Girard, Y. Pansart, and J. Lorette Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats Dig Dis Sci 48 2003 770 774
65. S. Sougioultzis, S. Simeonidis, and K.R. Bhaskar Saccharomyces boulardii produces soluble anti-inflammatory factor that inhibits NF-KB-mediated IL-8 gene expression Gastroenterology 125 2003 606
66. C.P. Kelly, C. Pothoulakis, and J.T. LaMont Pseudomembranous colitis N Engl J Med 330 1994 257 262
67. R. Benoit, D. Dorval, and J. Loulergue Diarrhée postantibiotique: rôle de Klebsiella oxytoca Gastroenterol Clin Biol 16 1992 860 864
68. L.V. McFarland Risk factors for antibiotic-associated diarrhea. A review of the literature Ann Med Interne 149 1998 261 266
69. J. Adam, A. Barret, and C. Barret-Ballet Essais cliniques contrôlés en double insu de l'Ultra-Levure lyophilisée. Etude multi-centrique par 25 médecins de 388 cas Med Chir Dig 5 1976 401 405
70. C.M. Surawicz, L.V. McFarland, and G. Elmer Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii Am J Gastroenterol 84 1989 1285 1287
71. P. Chapoy Traitement des diarrhées aiguës infantiles: essai contrôlé de Saccharomyces boulardii Ann Pediatr 32 1985 561 563
72. J.D. Tempe, A.L. Steidel, and H. Bléhaut Prévention par Saccharomyces boulardii des diarrhées de l'alimentation enérale à debit continu Sem Hop Paris 59 1983 1409 1412
73. M. Schlotterer, P. Bernasconi, and F. Lebreton Intérêt de Saccharomyces boulardii dans la tolérance digestive de la nutrition entérale à débit continu chez le brûlé Nutrition Clinique Metabolisme 1 1987 31 34
74. T. Saint-Marc, H. Bléhaut, and C. Musial Diarrhée en relation avec le SIDA. Essai en double aveugle de Saccharomyces boulardii Sem Hop Paris 71 1995 735 741
75. J.L. Maupas, P. Champemont, and M. Delforge Traitement des colopathies fonctionnelles. Essai en double aveugle de l'Ultra-Levure (treatment of irritable bowel syndrome with Saccharomyces boulardii: a double blind, placebo controlled study) Med Chir Dig 12 1983 77 79
76. C. Hennequin, C. Kauffman-Lacroix, and A. Jobert Possible role of catheters in Saccharomyces boulardii fungemia Eur J Clin Microbiol Infect Dis 19 2000 16 20
77. J. Perapoch, A.M. Places, and A. Querol Fungemia with Saccharomyces boulardii, only one of whom had been treated with Ultra-Levure Eur J Clin Microbiol Infect Dis 19 2000 468 470